^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Plasma-SeqSensei™ CRC Kit

Company:
Sysmex Corp
Type:
Laboratory Developed Test
Related tests:

Details

Evidence
Plasma-SeqSensei™ (PSS) CRC RUO Kit allows the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from plasma of patients with colorectal cancer (CRC). The kit is based on the next-generation sequencing technology and covers key mutations of the MAPK signaling genes KRAS, NRAS and BRAF and the PIK3CA genes. These genes significantly contribute to the development of colorectal cancer and are important biomarkers utilised for prognosis, choice of therapy, as well as monitoring of recurrence and therapy response.
Cancer:
Colorectal Cancer
Gene:
KRAS (KRAS proto-oncogene GTPase), NRAS (Neuroblastoma RAS viral oncogene homolog), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
Method:
Next-Generation Sequencing (NGS) / Circulating tumor DNA (ctDNA)